Yet, due to COVID −19 pandemic crisis, Eisai Co., Ltd. is participating in the global network REMAP-CAP-COVID (Randomized, Embedded, Multi-factorial, Adaptive Platform-Community Acquired Pneumonia COVID), which aims at developing therapeutics drugs for the novel coronavirus through drug repurposing, hoping to control the cytokine storm and prevent pneumonia complications through inhibiting the activation of TLR4 located at the uppermost stream of various cytokine production signals that cause cytokine storms, involved in the aggravation of pneumonia caused by coronavirus.67 This evidence concerns the gene TLR4 and pneumonia.